Markus Heller, PhD

Markus Heller, PhD has a diverse work experience in the scientific field. In 2021, they joined OpenEye Scientific as a Scientific Liaison. Prior to that, from 2019 to 2020, they worked at adMare BioInnovations as a Senior Scientist, where they conducted virtual screens for multiple projects and optimized hit compounds as part of Medicinal Chemistry project teams. Markus also provided NMR services to external clients and maintained adMare's NMR facility and screening compound database.

From 2008 to 2019, Markus worked at the Centre for Drug Research and Development (CDRD) as a Senior Scientist. Markus conducted virtual screens for multiple projects and optimized hit compounds as part of Medicinal Chemistry project teams. In 2019, CDRD merged with Neomed to form adMare Bioinnovations.

Prior to their work at CDRD, Markus worked at the University of British Columbia as a Post Doc from 2005 to 2007. Here, they characterized a novel, secondary xylan binding site using NMR-derived protein dynamics and determined the structure of a tricyclic peptide capable of inhibiting tumor cell invasion.

Additionally, Markus worked as a Post Doc at Technische Universität München from August 2004 to December 2004. During this time, their specific role or responsibilities are not provided in the information given.

Markus Heller completed their Doctorate (PhD) degree in Chemistry from the Technical University of Munich, from the year 2001 to 2004.